DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,973 | -57.2% | 12,941 | -38.8% | 0.07% | -56.1% |
| Q2 2023 | $623,546 | +54.8% | 21,130 | +20.9% | 0.16% | +43.5% |
| Q1 2023 | $402,716 | -5.6% | 17,479 | +14.0% | 0.11% | -6.9% |
| Q4 2022 | $426,550 | -9.4% | 15,338 | 0.0% | 0.12% | -10.1% |
| Q3 2022 | $471,000 | +29.0% | 15,338 | +23.5% | 0.13% | +41.8% |
| Q2 2022 | $365,000 | -8.5% | 12,416 | 0.0% | 0.09% | +8.3% |
| Q1 2022 | $399,000 | -28.0% | 12,416 | 0.0% | 0.08% | -18.4% |
| Q4 2021 | $554,000 | +45.4% | 12,416 | +64.5% | 0.10% | +33.8% |
| Q3 2021 | $381,000 | +42.7% | 7,547 | +121.4% | 0.08% | +48.1% |
| Q2 2021 | $267,000 | – | 3,408 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |